Heidy King-Jones - 09 Jan 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Reporting relationship: Chief Legal Officer and Corporate Secretary
Issuer ticker: SYRE
Reported as of: 09 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jan 2026, 21:25:34 UTC
Prior SEC filing: 17 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Heidy King-Jones

Key filing fact

Heidy King-Jones filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 13 Jan 2026.

Key facts

This page summarizes Heidy King-Jones's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jan 2026, 21:25.

Change

Previous filing in this sequence was filed on 17 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001794898 Primary reporting owner

King-Jones Heidy

Relationship: Chief Legal Officer and Corporate Secretary
Address: 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM
Signature: /s/ Heidy King-Jones
Signature date: 13 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SYRE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +140,000
Change %
Price: $0.000000
Shares after: 140,000
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 140,000
Exercise price: $30.61
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase 140,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

SEC remarks

Chief Legal Officer and Corporate Secretary